Dr. Mjalli is an internationally recognized expert in drug discovery and development of new medicines in the pharmaceutical and biotechnology industry. Dr. Mjalli is the founder, Chairman of the Board, President & CEO of TransTech Pharma, Inc., a drug discovery and development company and currently serves as Chairman of the Board of PharmaCore a drug discovery tool company, having previously been its founder, President and CEO. Dr. Mjalli obtained his Ph.D. in medicinal chemistry in 1989 from the University of Exeter, UK. His postdoctoral work was carried out at the University of Rochester. Dr. Mjalli has held various positions of increasing responsibility in research and senior management at several pharmaceutical and biotechnology companies including Merck & Co., Inc. and Ontogen Corporation. He is the author of more than 40 scientific papers, four book chapters and an inventor on more than 700 patents and patent applications. Dr. Mjalli also serves on the Board of Directors of Siga Technologies, the High Point Economic Development Corporation, the High Point University, the Arab American University and the American Task Force of Palestine. Dr. Mjalli has raised more than $120M for TransTech Pharma and PharmaCore, and more than $200M in revenue for TransTech.